Gaurav Shah, CEO - Rocket Pharmaceuticals (RCKT)
Gaurav Shah, M.D., stands at the forefront of biotechnology innovation as the CEO and co-founder of Rocket Pharmaceuticals (NASDAQ: RCKT). The company is dedicated to pioneering gene therapies for rare and devastating diseases. “Our mission is to seek gene therapy cures for patients with devastating rare diseases through the most innovative science and platforms to fulfill the promise of gene therapy for the betterment of our industry, science and humanity,” says Dr. Shah.
Dr. Shah’s academic and medical background laid a solid foundation for his biotechnology career. Graduating summa cum laude from Harvard College with a degree in Behavioral Neuroscience, he earned his M.D. from Columbia University, where he was inducted into the prestigious Alpha Omega Alpha honor society. Dr. Shah completed his residency in internal medicine at Brigham and Women’s Hospital and a fellowship in hematology and oncology at Memorial Sloan Kettering Cancer Center. As a board-certified oncologist, he served as an Adjunct Assistant Professor of Oncology at Columbia University before transitioning to the pharmaceutical industry.
At ImClone Systems, a subsidiary of Eli Lilly, Dr. Shah began his industry career as a Medical Director overseeing oncology trials involving monoclonal antibodies. He later joined Novartis and played a pivotal role as Global Program Head in the Cell & Gene Therapies Unit, leading groundbreaking clinical trials for leukemia and lymphoma therapies.
Since founding Rocket Pharmaceuticals, Dr. Shah has guided the company to significant milestones in developing gene therapies for rare diseases. Under his leadership, the company has developed a robust pipeline of clinical programs targeting rare diseases, with four programs currently in clinical trials focused on conditions such as Fanconi anemia, severe leukocyte adhesion deficiency-I (LAD-I), pyruvate kinase deficiency (PKD), and infantile malignant osteopetrosis (IMO).
Rocket has also made remarkable regulatory progress, successfully submitting a Biologics License Application (BLA) for its LV-based gene therapy for LAD-I, which has been accepted by the FDA and granted priority review, paving the way for potential approval and commercialization.
In addition to these accomplishments, Rocket Pharmaceuticals has received multiple FDA designations, including Fast Track and Orphan Drug Designations for five of its programs and Regenerative Medicine Advanced Therapy (RMAT) designations for four programs, expediting the development and review of therapies for serious conditions. Dr. Shah’s leadership has also driven the establishment of in-house cGMP manufacturing capabilities, significantly enhancing the company’s ability to produce gene therapies efficiently, supporting ongoing clinical trials, and positioning the company for future commercialization.
In December 2022, Rocket Pharmaceuticals strategically acquired Renovacor, enhancing its capabilities in AAV-based cardiac gene therapy. This acquisition expanded the firm’s portfolio and bolstered its intellectual property for addressing severe heart conditions.
In addition to these accomplishments, Rocket Pharmaceuticals has received multiple FDA designations, including Fast Track and Orphan Drug Designations for five of its programs and Regenerative Medicine Advanced Therapy (RMAT) designations for four programs, expediting the development and review of therapies for serious conditions. Dr. Shah’s leadership has also driven the establishment of in-house cGMP manufacturing capabilities, significantly enhancing the company’s ability to produce gene therapies efficiently, supporting ongoing clinical trials, and positioning the company for future commercialization.
In December 2022, Rocket Pharmaceuticals strategically acquired Renovacor, enhancing its capabilities in AAV-based cardiac gene therapy. This acquisition expanded the firm’s portfolio and bolstered its intellectual property for addressing severe heart conditions.
"Our mission is to seek gene therapy cures for patients with devastating rare diseases through the most innovative science and platforms to fulfill the promise of gene therapy for the betterment of our industry, science and humanity. "
Financially, Rocket Pharmaceuticals remains robust, with approximately $400 million in cash reserves as of early 2023, providing operational stability and funding for ongoing research through 2024. The company’s innovative approaches have earned recognition in the scientific community, with presentations at major conferences such as the American Society of Gene and Cell Therapy (ASGCT) and positive data from its clinical trials bolstering its reputation in the gene therapy landscape.
Guided by Dr. Shah’s vision, Rocket Pharmaceuticals delivers transformative treatments for rare genetic disorders and contributes to the advancement of gene therapy science. The company’s innovative approaches and clinical successes position it as a leader in the field, committed to improving lives through cutting-edge medical science.